This company listing is no longer active
DNL Stock Overview
Diurnal Group plc operates as a specialty pharma company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Diurnal Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.27 |
| 52 Week High | UK£0.68 |
| 52 Week Low | UK£0.095 |
| Beta | 0.35 |
| 1 Month Change | 0.55% |
| 3 Month Change | 180.00% |
| 1 Year Change | -54.65% |
| 3 Year Change | -14.69% |
| 5 Year Change | -80.84% |
| Change since IPO | -82.16% |
Recent News & Updates
Recent updates
Diurnal Group (LON:DNL) Will Have To Spend Its Cash Wisely
Aug 13
Shareholders May Not Be So Generous With Diurnal Group plc's (LON:DNL) CEO Compensation And Here's Why
Nov 13Companies Like Diurnal Group (LON:DNL) Can Afford To Invest In Growth
Feb 25What Can We Learn About Diurnal Group's (LON:DNL) CEO Compensation?
Feb 04Diurnal Group plc (LON:DNL): When Will It Breakeven?
Jan 14Diurnal Group (LON:DNL) Shareholders Have Enjoyed A 88% Share Price Gain
Dec 25Estimating The Fair Value Of Diurnal Group plc (LON:DNL)
Dec 02Shareholder Returns
| DNL | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 2.2% |
| 1Y | -54.7% | -14.3% | 2.4% |
Return vs Industry: DNL underperformed the UK Biotechs industry which returned -42.3% over the past year.
Return vs Market: DNL underperformed the UK Market which returned -13.8% over the past year.
Price Volatility
| DNL volatility | |
|---|---|
| DNL Average Weekly Movement | 38.5% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 3.3% |
Stable Share Price: DNL's share price has been volatile over the past 3 months.
Volatility Over Time: DNL's weekly volatility has increased from 21% to 39% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 33 | Richard Bungay | www.diurnal.co.uk |
Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers an oral formulation of hydrocortisone granules in capsules for the treatment of pediatric adrenal insufficiency.
Diurnal Group plc Fundamentals Summary
| DNL fundamental statistics | |
|---|---|
| Market cap | UK£47.74m |
| Earnings (TTM) | -UK£16.57m |
| Revenue (TTM) | UK£4.68m |
Is DNL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DNL income statement (TTM) | |
|---|---|
| Revenue | UK£4.68m |
| Cost of Revenue | UK£1.02m |
| Gross Profit | UK£3.66m |
| Other Expenses | UK£20.23m |
| Earnings | -UK£16.57m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.095 |
| Gross Margin | 78.16% |
| Net Profit Margin | -353.76% |
| Debt/Equity Ratio | 0.0% |
How did DNL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/11/02 02:38 |
| End of Day Share Price | 2022/11/01 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Diurnal Group plc is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian White | Cantor Fitzgerald Europe |
| Michael Foster | Hardman & Co. |
| Michael Mitchell | Panmure Liberum Historic (Panmure Gordon) |